Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2006 December;58(6) > Minerva Ginecologica 2006 December;58(6):459-70



To subscribe
Submit an article
Recommend to your librarian





Minerva Ginecologica 2006 December;58(6):459-70


language: Italian

Up-date on cytoreductive surgery in the management of advanced ovarian cancer

Angioli R., Palaia I., Damiani P., Montera R., Benedetti Panici P.

1 Dipartimento di Ostetricia e Ginecologia Università Campus Bio-Medico di Roma, Roma 2 Dipartimento di Ostetricia e Ginecologia Università di Roma La Sapienza, Roma


Epithelial ovarian cancer represents the most aggressive neoplasm of women genital apparatus with a total 5-year survival rate ranging from 17% to 35% if the disease is in the metastatic phase. Its aggressiveness derives from the fact that it is an asymptomatic disease until it spreads in abdominal cavity. Therefore, in 70% of the cases, the diagnosis is done when tumor is already in advanced phase (Stage FIGO IIB-IV). Data from international literature suggest that standard treatment for advanced ovarian cancer is optimal cytoreductive surgery with adjuvant chemotherapy platinum-based. Howe-ver, in the last decades, many authors have described the enthusiastic results of neoadjuvant chemotherapy and interval debulking surgery. Griffiths, first, underlined the importance of residual mass after cytoreductive surgery as a prognostic factor. Currently, cytoreduction is defined optimal when residual mass is microscopical or absent. Nevertheless, surgery for ovarian cancer turns out to be a particularly aggressive surgery that needs an operator’s remarkable technical ability and a cultural background. Many studies demonstrated that the frequency of feasibility of optimal cytoreductive surgery also varies within the gynecologic oncology specialized centers. During the last few years, new technologies (such as Cavitron Ultrasonic Surgical Aspirator, CUSA, and argon’s coagulator) and new surgical techniques have been introduced. Ovarian cancer turns out to be a particularly chemosensitive tumor. Its responsiveness has been the object of numerous studies and protocols in literature, such as European Organisation of Research and Treatment of Cancer (EORTC) and Gynecologic Oncology Group (GOG) trials.

top of page